

# Anna R Michmerhuizen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7710195/publications.pdf>

Version: 2024-02-01

11  
papers

233  
citations

1307594

7  
h-index

1372567

10  
g-index

12  
all docs

12  
docs citations

12  
times ranked

288  
citing authors

#	ARTICLE	IF	CITATIONS
1	ARe we there yet? Understanding androgen receptor signaling in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 47.	5.2	57
2	TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination. <i>Journal of Clinical Investigation</i> , 2020, 130, 958-973.	8.2	53
3	PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2063-2073.	4.1	38
4	Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 6568-6580.	7.0	30
5	Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. <i>Frontiers in Endocrinology</i> , 2020, 11, 35.	3.5	24
6	A Signature That May Be Predictive of Early Versus Late Recurrence After Radiation Treatment for Breast Cancer That May Inform the Biology of Early, Aggressive Recurrences. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 686-696.	0.8	11
7	RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes. <i>JCI Insight</i> , 2022, 7, .	5.0	9
8	Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models. <i>Npj Breast Cancer</i> , 2022, 8, 31.	5.2	7
9	Bcl-xL Inhibition Radiosensitizes PIK3CA/PTEN Wild-type Triple-negative Breast Cancers with Low Mcl-1 Expression. <i>Cancer Research Communications</i> , 2022, 2, 679-693.	1.7	3
10	Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer. <i>British Journal of Cancer</i> , 2022, 127, 927-936.	6.4	1
11	Degrading AR-dependent cancers: Expanding the role of PROTACs. <i>Neoplasia</i> , 2020, 22, 533-535.	5.3	0